Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

FMT+ QL1706+ bevacizumab+ xelox come trattamento di prima linea per il carcinoma del colon di tipo MSS avanzato con metastasi epatiche

22 settembre 2026 aggiornato da: Hua Jiang

Trapianto di microbiota fecale combinato con QL1706, Bevacizumab e Xelox come trattamento di prima linea per il carcinoma del colon di tipo MSS avanzato con metastasi epatiche: protocollo di studio per un prospettico, multicentrico, a un braccio a braccio singolo di esplosione di fase II

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colorectal cancer patients with liver metastasis.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a prospective, single-arm, multi-center, exploratory clinical study. Patients with previously untreated, newly diagnosed advanced colorectal cancer with liver metastasis, who could be diagnosed by histological or cytological means, ECOG PS 0-1, excluded Ras, Raf wild type left colon/rectum, excluded dMMR/MSI-H. Eligible subjects who met the inclusion criteria were screened and signed informed consent.

FMT was performed 2 days after treatment with bevacizumab, and chemotherapy. QL1706, bevacizumab, and chemotherapy (XELOX) were administered every 3 weeks according to the patient's body surface area. A total of 6 cycles were performed. Subsequent maintenance therapy was at the discretion of the investigator.

RECIST v1.1 was used for tumor evaluation every 6 weeks during treatment. NCI-CTCAE 5.0 was used for safety assessment every 3 weeks. Adverse events were recorded throughout the study to 90 days after the end of treatment. Treatment continues until disease progression, subject withdraws informed consent, loss of follow-up, or death. Patients should provide 10ml whole blood samples and fecal samples at baseline, after two cycles of treatment, after four cycles of treatment, before maintenance treatment for the detection of efficacy prediction markers (each cycle is 21 days).

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Changzhou, Cina
        • Reclutamento
        • The Second People's Hospital of Changzhou
        • Contatto:
          • Hua Jiang MD
          • Numero di telefono: +86-18015852711

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Histological or cytological confirmed advanced colorectal cancer with liver metastasis.
  2. Signed written informed consent.
  3. Have not received anti-tumor treatment.
  4. According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
  5. Patients of both sexes, aged ≥18 years and ≤75 years.
  6. ECOG PS 0-1;
  7. Expected survival time ≥ 3 months;
  8. Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:

1) Blood routine: ANC ≥ 1.5 × 10^9/L, Platelet count ≥ 100 × 10^9/L, HGB ≥100 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT/AST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL/min: Urine routine results showed urinary protein < 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.

10. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.

11. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.

Exclusion Criteria:

  1. Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.
  2. Patients requiring elective surgery during the trial.
  3. Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.
  4. Patients during pregnancy (positive pregnancy test) or lactation.
  5. Central nervous system metastasis or meningeal metastasis.
  6. Uncontrollable bone metastasis, or patients at risk of fracture, requiring surgery, local radiation therapy.
  7. Patients with active infection requiring systemic anti-infection treatment.
  8. Patients with a history of immunodeficiency, including those who are positive for HIV antibody tests.
  9. Patients with known, active autoimmune diseases.
  10. Patients with uncontrolled active hepatitis B, patients with hepatitis C virus infection (HCV antibody positive).
  11. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe arrhythmia, acute coronary syndrome within 6 months, congestive heart failure, aortic dissection, stroke, and T IA history.
  12. Severe bleeding events occur within half a year, or high bleeding risk factors such as active digestive tract ulcers and esophageal and gastric varices due to liver cirrhosis.
  13. Patients with diabetes who cannot be stably controlled by drugs (including insulin).
  14. Mental or language disorders that prevent communication with the patient;
  15. Patients participating in another clinical trial.
  16. MSI-H/ d MMR without immunotherapy; left colorectum of Ras, Raf wild-type.
  17. The investigator believes that the subject has other serious systemic diseases or other conditions that make him unsuitable for participation in this trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: FMT+QL1706+bevacizumab+xelox

Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response Rate (ORR)
Lasso di tempo: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Median Progression-Free Survival (mPFS)
Lasso di tempo: up to 24 months

Observation for mPFS will be recorded until the end of follow-up after the start of 1st cycle of treatment.

up to 24 months
Median Overall Survival (mOS)
Lasso di tempo: up to 24 months

The time from the first treatment to death from any cause.

up to 24 months
6-Months Progression-Free Survival Rate (6month-PFS)
Lasso di tempo: up to 6 months

The proportion of patients whose disease did not progress 6 months after treatment

up to 6 months
12-Months Progression-Free Survival Rate (12month-PFS)
Lasso di tempo: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months Progression-Free Survival Rate (18month-PFS)
Lasso di tempo: up to 18 months

The proportion of patients whose disease did not progress 18 months after treatment

up to 18 months
6-Months overall survival rate(6-Months-OS Rate)
Lasso di tempo: up to 6 months

The proportion of patients who have not died after 6-Months of treatment

up to 6 months
12-Months overall survival rate(12-Months-OS Rate)
Lasso di tempo: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months overall survival rate(18-Monthsr-OS Rate)
Lasso di tempo: up to 18 months

The proportion of patients who have not died after 18 months of treatment

up to 18 months
Objective Response Rate (ORR) of liver metastases
Lasso di tempo: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months
Disease Control Rate (DCR)
Lasso di tempo: up to 24 months

The proportion of patients whose tumors achieve a response (CR+PR) and stable disease (SD) after treatment for the minimum duration required.

up to 24 months
Surgical conversion rate
Lasso di tempo: up to 24 months

Proportion of inoperable patients converted to operable.

up to 24 months
Incidence of Adverse events (AEs)
Lasso di tempo: up to 24 months

Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 24 months
Quality of Life (QoL)
Lasso di tempo: up to 24 months

QoL(quality of life) will be evaluated by EORTC-QLQ-C30.The total score ranges from 0 to 60, with higher scores indicating better quality of life

up to 24 months
The Diversity of Fecal Microbiota
Lasso di tempo: up to 24 months

This will be detected by 16s rRNA sequencing or metagenomes.

up to 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 aprile 2025

Completamento primario (Stimato)

1 febbraio 2027

Completamento dello studio (Stimato)

1 febbraio 2027

Date di iscrizione allo studio

Primo inviato

25 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

25 gennaio 2025

Primo Inserito (Effettivo)

30 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • [2025]YLJSA057-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .